Mode of action of RU 486.
RU 486 is a 19-norsteroid which has a specific high affinity binding to the progesterone and glucocorticoid receptor. It is generally accepted that RU 486 acts as a pure progesterone antagonist almost without agonistic activity. RU 486 acts mainly directly on the target organ, such as the endometrium, but also to some extent indirectly through an effect on the pituitary gonadotrophin secretion. The effect of RU 486 during the menstrual cycle is dependent on time of treatment. Treatment before ovulation will result in a prolongation of the proliferative phase of the menstrual cycle, while treatment during the mid- and late luteal phase will invariably induce bleeding, often followed by a second bleeding episode at the expected time of menstruation. The only treatment period which does not influence the menstrual cycle is treatment immediately following ovulation. Treatment during the proliferative phase has no effect on endometrial morphology but inhibits follicular development and delays oestrogen and LH surge. Treatment on the first days following ovulation has no effect on ovarian steroid concentration, but will significantly delay endometrial development, cause a change in the concentration of oestrogen and progesterone receptor concentration enzyme activity and production of substances thought to be progesterone dependent. The change in endometrial development is sufficient to prevent implantation. In mid- and late luteal phase, treatment with RU 486 will result in endometrial shedding in spite of normal progesterone levels. Post-ovulatory treatment with RU 486 will also significantly change uterine contractility. In early pregnancy, withdrawal of progesterone inhibition will result in uterine contractility and a significant increase in the sensitivity of the myometrium to prostaglandin.(ABSTRACT TRUNCATED AT 250 WORDS)
Bygdeman
M
M
Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden.
Swahn
M L
ML
Gemzell-Danielsson
K
K
Svalander
P
P
D000028:Abortion, Induced; D004717:Endometrium / Q000187:drug effects; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D015735:Mifepristone / Q000494:pharmacology*; D011247:Pregnancy / Q000187:drug effects; D011980:Receptors, Progesterone / Q000187:drug effects; D014590:Uterine Contraction / Q000187:drug effects
D011980:Receptors, Progesterone; D015735:Mifepristone